Suppr超能文献

钙稳态失衡的逆转:治疗阿尔茨海默病的潜在方法。

Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease.

机构信息

Laboratory of Molecular Neurodegeneration, Peter the Great St Petersburg Polytechnic University, St Petersburg, Russian Federation.

Department of Physiology, UT Southwestern Medical Center, Dallas, TX 75390, United States.

出版信息

Curr Alzheimer Res. 2020;17(4):344-354. doi: 10.2174/1567205017666200528162046.

Abstract

Despite decades of research and effort, there is still no effective disease-modifying treatment for Alzheimer's Disease (AD). Most of the recent AD clinical trials were targeting amyloid pathway, but all these trials failed. Although amyloid pathology is a hallmark and defining feature of AD, targeting the amyloid pathway has been very challenging due to low efficacy and serious side effects. Alternative approaches or mechanisms for our understanding of the major cause of memory loss in AD need to be considered as potential therapeutic targets. Increasing studies suggest that Ca2+ dysregulation in AD plays an important role in AD pathology and is associated with other AD abnormalities, such as excessive inflammation, increased ROS, impaired autophagy, neurodegeneration, synapse, and cognitive dysfunction. Ca2+ dysregulation in cytosolic space, Endoplasmic Reticulum (ER) and mitochondria have been reported in the context of various AD models. Drugs or strategies, to correct the Ca2+ dysregulation in AD, have been demonstrated to be promising as an approach for the treatment of AD in preclinical models. This review will discuss the mechanisms of Ca2+ dysregulation in AD and associated pathology and discuss potential approaches or strategies to develop novel drugs for the treatment of AD by targeting Ca2+ dysregulation.

摘要

尽管经过了几十年的研究和努力,但目前仍没有针对阿尔茨海默病(AD)的有效治疗方法。大多数最近的 AD 临床试验都针对淀粉样蛋白途径,但所有这些试验都失败了。尽管淀粉样蛋白病理学是 AD 的标志和定义特征,但由于疗效低和严重的副作用,靶向淀粉样蛋白途径一直极具挑战性。需要考虑其他方法或机制来理解 AD 中记忆丧失的主要原因,将其作为潜在的治疗靶点。越来越多的研究表明,AD 中的钙失调在 AD 病理学中起着重要作用,并与 AD 的其他异常有关,如过度炎症、增加的 ROS、自噬受损、神经退行性变、突触和认知功能障碍。在各种 AD 模型中,已经报道了细胞溶质空间、内质网(ER)和线粒体中的 Ca2+ 失调。在临床前模型中,纠正 AD 中 Ca2+ 失调的药物或策略已被证明具有治疗 AD 的潜力。本综述将讨论 AD 中 Ca2+ 失调的机制及其相关病理学,并讨论通过靶向 Ca2+ 失调开发治疗 AD 的新型药物的潜在方法或策略。

相似文献

2
Dysregulation of Intracellular Calcium Signaling in Alzheimer's Disease.阿尔茨海默病患者细胞内钙信号失调。
Antioxid Redox Signal. 2018 Oct 20;29(12):1176-1188. doi: 10.1089/ars.2018.7506. Epub 2018 Aug 3.
4
The dysregulation of intracellular calcium in Alzheimer disease.阿尔茨海默病患者细胞内钙离子的失调。
Cell Calcium. 2010 Feb;47(2):183-9. doi: 10.1016/j.ceca.2009.12.014. Epub 2010 Jan 18.
5
Dysregulation of calcium homeostasis in Alzheimer's disease.阿尔茨海默病中钙稳态的失调。
Neurochem Res. 2009 Oct;34(10):1824-9. doi: 10.1007/s11064-009-9960-5. Epub 2009 Apr 1.

引用本文的文献

6
Soluble Aβ Oligomers Formed Channels Leading to Calcium Dysregulation.可溶性Aβ寡聚体形成导致钙调节异常的通道。
Function (Oxf). 2023 Jul 17;4(5):zqad037. doi: 10.1093/function/zqad037. eCollection 2023.

本文引用的文献

1
Clinical trials of new drugs for Alzheimer disease.治疗阿尔茨海默病新药的临床试验。
J Biomed Sci. 2020 Jan 6;27(1):18. doi: 10.1186/s12929-019-0609-7.
2
Ketamine: A Neglected Therapy for Alzheimer Disease.氯胺酮:一种被忽视的阿尔茨海默病治疗方法。
Front Aging Neurosci. 2019 Jul 24;11:186. doi: 10.3389/fnagi.2019.00186. eCollection 2019.
7
New evolutions in the BACE1 inhibitor field from 2014 to 2018.2014 年至 2018 年 BACE1 抑制剂领域的新进展。
Bioorg Med Chem Lett. 2019 Mar 15;29(6):761-777. doi: 10.1016/j.bmcl.2018.12.049. Epub 2019 Jan 4.
9
Recognition of the amyloid precursor protein by human γ-secretase.人γ-分泌酶对淀粉样前体蛋白的识别。
Science. 2019 Feb 15;363(6428). doi: 10.1126/science.aaw0930. Epub 2019 Jan 10.
10
Structural basis of Notch recognition by human γ-secretase.人 γ-分泌酶识别 Notch 的结构基础。
Nature. 2019 Jan;565(7738):192-197. doi: 10.1038/s41586-018-0813-8. Epub 2018 Dec 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验